Thrombophilia risk factors are associated with intrauterine foetal death and pregnancy‐related venous thromboembolism

References

• Bremme K. A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153–68
   PubMed Web of Science ®Google Scholar
• Stirling Y., Woolf L., North W. R., Seghatchian M. J., Meade T. W. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176–82
   PubMed Web of Science ®Google Scholar
• Bonnar J. Haemostasis and coagulation disorders in pregnancy. Haemostasis and thrombosis, A. L Bloom, D. P Thomas. Churchill Livingstone, Edinburgh 1987; 570–84
   Google Scholar
• Beller F. K., Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177–97
   PubMed Web of Science ®Google Scholar
• Comp P. C., Thurnau G. R., Welsh J., Esmon C. T. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68: 881–5
   PubMed Web of Science ®Google Scholar
• Malm J., Laurell M., Dahlback B. Changes in the plasma levels of vitamin K‐dependent proteins C and S and of C4b‐binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437–43
   PubMed Web of Science ®Google Scholar
• Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166–70
   PubMed Web of Science ®Google Scholar
• Cumming A. M., Tait R. C., Fildes S., Yoong A., Keeney S., Hay C. R. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725–7
   PubMed Web of Science ®Google Scholar
• Mathonnet F., de Mazancourt P., Bastenaire B., Morot M., Benattar N., Beufe S., Borg J. Y., Giudicelli Y. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996; 92: 244–6
   PubMed Web of Science ®Google Scholar
• Ishii A., Yamada S., Yamada R., Hamada H. t‐PA activity in peripheral blood obtained from pregnant women. J Perinat Med 1994; 22: 113–17
   PubMed Web of Science ®Google Scholar
• Lecander I., Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221–8
   PubMed Web of Science ®Google Scholar
• Wright J. G., Cooper P., Astedt B., Lecander I., Wilde J. T., Preston F. E., Greaves M. Fibrinolysis during normal human pregnancy: complex inter‐relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253–8
   PubMed Web of Science ®Google Scholar
• Gerbasi F. R., Bottoms S., Farag A., Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75: 385–9
   PubMed Web of Science ®Google Scholar
• De Santis M., Cavaliere A. F., Straface G., Di Gianantonio E., Caruso A. Inherited and acquired thrombophilia: pregnancy outcome and treatment. Reprod Toxicol 2006; 22: 227–33
   PubMed Web of Science ®Google Scholar
• Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101: 6–14
   PubMed Web of Science ®Google Scholar
• Triplett D. A. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15: 173–8
   PubMedGoogle Scholar
• Whitcombe D., Brownie J., Gillard H. L., McKechnie D., Theaker J., Newton C. R., Little S. A homogeneous fluorescence assay for PCR amplicons: its application to real‐time, single‐tube genotyping. Clin Chem 1998; 44: 918–23
   PubMed Web of Science ®Google Scholar
• Larsen T. B., Lassen J. F., Brandslund I., Byriel L., Petersen G. B., Norgaard‐Pedersen B. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 1998; 89: 211–15
   PubMedGoogle Scholar
• Emmerich J., Rosendaal F. R., Cattaneo M., Margaglione M., De S. V., Cumming T., Arruda V., Hillarp A., Reny J. L. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism – pooled analysis of 8 case‐control studies including 2310 cases and 3204 controls. Study Group for Pooled‐Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809–16
   PubMed Web of Science ®Google Scholar
• Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145–51
   PubMed Web of Science ®Google Scholar
• Lindqvist P., Dahlback B., Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595–9
   PubMed Web of Science ®Google Scholar
• Walker I. D. Venous and arterial thrombosis during pregnancy: epidemiology. Semin Vasc Med 2003; 3: 25–32
   PubMedGoogle Scholar
• Stein P. D., Hull R. D., Kayali F., Olson R. E., Alshab A. K., Meyers F. A., Ghali W. A., Silbergleit A., Gibson P. Venous thromboembolism in pregnancy: 21‐year trends. Am J Med 2004; 117: 121–5
   PubMedGoogle Scholar
• Greer I. A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258–65
   PubMed Web of Science ®Google Scholar
• MacLean M. A., Cumming G. P., McCall F., Walker I. D., Walker J. J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101: 103–6
   PubMedGoogle Scholar
• McColl M. D., Ramsay J. E., Tait R. C., Walker I. D., McCall F., Conkie J. A., Carty M. J., Greer I. A. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183–8
   PubMed Web of Science ®Google Scholar
• von Tempelhoff G. F., Heilmann L., Spanuth E., Kunzmann E., Hommel G. Incidence of the factor V Leiden‐mutation, coagulation inhibitor deficiency, and elevated antiphospholipid‐antibodies in patients with preeclampsia or HELLP‐syndrome. Hemolysis, elevated liver‐enzymes, low platelets. Thromb Res 2000; 100: 363–5
   PubMed Web of Science ®Google Scholar
• Gerhardt A., Scharf R. E., Beckmann M. W., Struve S., Bender H. G., Pillny M., Sandmann W., Zotz R. B. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374–80
   PubMed Web of Science ®Google Scholar
• Gerhardt A., Scharf R. E., Zotz R. B. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77–85
   PubMed Web of Science ®Google Scholar
• Price D. T., Ridker P. M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895–903
   PubMed Web of Science ®Google Scholar
• Lissalde‐Lavigne G., Fabbro‐Peray P., Cochery‐Nouvellon E., Mercier E., Ripart‐Neveu S., Balducchi J. P., Daures J. P., Perneger T., Quere I., Dauzat M., Mares P., Gris J. C. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case‐control ‘NOHA first’ study. J Thromb Haemost 2005; 3: 2178–84
   PubMed Web of Science ®Google Scholar
• Dudding T. E., Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta‐analysis. Thromb Haemost 2004; 91: 700–11
   PubMed Web of Science ®Google Scholar
• Kovalevsky G., Gracia C. R., Berlin J. A., Sammel M. D., Barnhart K. T. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta‐analysis. Arch Intern Med 2004; 164: 558–63
   PubMed Web of Science ®Google Scholar
• Rey E., Kahn S. R., David M., Shrier I. Thrombophilic disorders and fetal loss: a meta‐analysis. Lancet 2003; 361: 901–8
   PubMed Web of Science ®Google Scholar
• Mtiraoui N., Borgi L., Hizem S., Nsiri B., Finan R. R., Gris J. C., Almawi W. Y., Mahjoub T. Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005; 119: 164–70
   PubMed Web of Science ®Google Scholar
• Triplett D. A., Harris E. N. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 1989; 21: 123–31
   PubMed Web of Science ®Google Scholar
• Clark P., Walker I. D., Govan L., Wu O., Greer I. A. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol 2008; 140: 236–40
   PubMed Web of Science ®Google Scholar
• Dizon‐Townson D., Miller C., Sibai B., Spong C. Y., Thom E., Wendel G Jr., et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106: 517–24
   PubMed Web of Science ®Google Scholar
• Nurk E., Tell G. S., Refsum H., Ueland P. M., Vollset S. E. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM 2006; 99: 289–98
   PubMed Web of Science ®Google Scholar
• Kupferminc M. J., Eldor A., Steinman N., Many A., Bar‐Am A., Jaffa A., Fait G., Lessing J. B. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9–13
   PubMed Web of Science ®Google Scholar
• De Maat M. P., Jansen M. W., Hille E. T., Vos H. L., Bloemenkamp K. W., Buitendijk S., Helmerhorst F. M., Wladimiroff J. W., Bertina R. M., Groot C. J. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004; 2: 1588–93
   PubMed Web of Science ®Google Scholar
• van Pampus M. G., Wolf H., Koopman M. M., van den E. A., Buller H. R., Reitsma P. H. Prothrombin 20210 G: a mutation and Factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. Hypertens Pregnancy 2001; 20: 291–8
   PubMed Web of Science ®Google Scholar
• Lindqvist P. G., Svensson P. J., Marsaal K., Grennert L., Luterkort M., Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532–7
   PubMed Web of Science ®Google Scholar
• Murphy R. P., Donoghue C., Nallen R. J., D'Mello M., Regan C., Whitehead A. S., Fitzgerald D. J. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266–70
   PubMed Web of Science ®Google Scholar
• Kupferminc M. J., Many A., Bar‐Am A., Lessing J. B., Ascher‐Landsberg J. Mid‐trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 2002; 109: 1373–6
   PubMed Web of Science ®Google Scholar
• Infante‐Rivard C., Rivard G. E., Yotov W. V., Genin E., Guiguet M., Weinberg C., Gauthier R., Feoli‐Fonseca J. C. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347: 19–25
   PubMed Web of Science ®Google Scholar
• Infante‐Rivard C., Rivard G. E., Guiguet M., Gauthier R. Thrombophilic polymorphisms and intrauterine growth restriction. Epidemiology 2005; 16: 281–7
   PubMedGoogle Scholar
• Prochazka M., Lubusky M., Slavik L., Hrachovec P., Zielina P., Kudela M., Lindqvist P. G. Frequency of selected thrombophilias in women with placental abruption. Aust NZ J Obstet Gynaecol 2007; 47: 297–301
   PubMed Web of Science ®Google Scholar
• Merriman L., Greaves M. Testing for thrombophilia: an evidence‐based approach. Postgrad Med J 2006; 82: 699–704
   PubMed Web of Science ®Google Scholar
• Brenner B. Thrombophilia and pregnancy. Hematology 2005; 10(Suppl 1)186–9
   PubMedGoogle Scholar
• Pabinger I., Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005; 3: 1603–10
   PubMed Web of Science ®Google Scholar